A phase 2b, dose-selection study evaluating the efficacy and safety of oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis (DOVE)

We present the results of this phase 2b study here with focus on clinical response at Day-25 (secondary endpoint).
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: IDSOG Abstract Source Type: research